Our laboratory has received a four-year renewal of its NIH/NHLBI R01 to investigate how phospho-MARCKS regulates macrophage reprogramming in tobacco smoke-driven pulmonary fibrosis. The project will combine mechanistic studies, genetic and pharmacological approaches, precision-cut lung slices, and patient-derived models to evaluate the MARCKS pathway as a potential therapeutic target.